Posted by Michael Wonder on 21 Dec 2020
Expanded PBS access to breakthrough medicine for lung cancer
20 December 2020 - A significant lung cancer treatment option that costs approximately $88,000 a year will soon be available for as little as $6.60 per script, thanks to its expanded listing on the Pharmaceutical Benefits Scheme.
From 1 January 2021, Australians living with non-small cell lung cancer who have not had prior therapy will benefit from the listing of Tagrisso (osimertinib).
